On May 16, 2016, Revive Therapeutics Ltd. (TSXV: RVV) announced a best efforts rights offering to raise $2.2 million. Revive is focused on commercializing treatments for gout, and rare diseases such as cystinuria, Wilson’s disease and Rett syndrome.
Peterson & Company LLP acted for Revive with a team that included Dennis Peterson.